Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Survodutide (BI 456906) Phase 2 in Obesity/Overweight
NCT04667377Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2021
- Primary completion
- Sep 2022
- Modality
- Peptides
- Countries
- 12
01
Overview
A Phase 2 trial of survodutide in obesity, Overweight, sponsored by Boehringer Ingelheim. Started Mar 2021; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT04667377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04667377.